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Summary
Background Insecticide-treated nets and intermittent preventive treatment with sulfadoxine–pyrimethamine are 
recommended for the control of malaria during pregnancy in endemic areas in Africa, but there has been no analysis 
of coverage data at a subnational level. We aimed to synthesise data from national surveys about these interventions, 
accounting for disparities in malaria risk within national borders.
Methods We extracted data for speciﬁ c strategies for malaria control in pregnant women from national malaria 
policies from endemic countries in Africa. We identiﬁ ed the most recent national household cluster-sample surveys 
recording intermittent preventive treatment with sulfadoxine–pyrimethamine and use of insecticide-treated nets. We 
reconciled data to subnational administrative units to construct a model to estimate the number of pregnant women 
covered by a recommended intervention in 2007.
Findings 45 (96%) of 47 countries surveyed had a policy for distribution of insecticide-treated nets for pregnant 
women; estimated coverage in 2007 was 4·7 million (17%) of 27·7 million pregnancies at risk of malaria in 
32 countries with data. 39 (83%) of 47 countries surveyed had an intermittent preventive treatment policy; in 2007, 
an estimated 6·4 million (25%) of 25·6 million pregnant women received at least one dose of treatment and 
19·8 million (77%) visited an antenatal clinic (31 countries). Estimated coverage was lowest in areas of high-intensity 
transmission of malaria.
Interpretation Despite success in a few countries, coverage of insecticide-treated nets and intermittent preventive 
treatment in pregnant African women is inadequate; increased eﬀ orts towards scale-up are needed.
Funding The Malaria in Pregnancy Consortium and Wellcome Trust.
Introduction
Malaria infection during pregnancy can lead to very poor 
outcomes for the mother and child.1 In 2007, there were 
about 32 million pregnancies in malaria-endemic areas 
in sub-Saharan Africa.2 WHO’s recommendation for 
malaria prevention and control during pregnancy in 
areas of stable malaria transmission in Africa is a package 
of intermittent preventive treatment and insecticide-
treated nets with eﬀ ective management of clinical malaria 
and anaemia, which is commonly delivered through 
collaboration between malaria and reproductive-health 
programmes.3 The recommended drug for intermittent 
preventive treatment is sulfadoxine–pyrimethamine. 
These interventions can substantially reduce disease 
burden and adverse outcomes of malaria in pregnancy,4–6 
and are cheap and cost eﬀ ective.7,8 The Roll Back Malaria 
initiative aims to ensure that all pregnant women receive 
intermittent preventive treatment and at least 80% of 
people at risk from malaria use insecticide-treated nets 
in areas of high-intensity transmission by 2010, including 
those who are pregnant.9
Achievement of high coverage of intermittent 
preventive treatment has remained elusive for many 
countries in sub-Saharan Africa,10 despite high use of 
antenatal care.11,12 Speciﬁ c targeting of pregnant women 
aimed at increased use of insecticide-treated nets began 
in sub-Saharan Africa earlier than did intermittent 
preventive treatment, but coverage is much lower than 
targets set by the Roll Back Malaria initiative.10 
Nevertheless, access to antenatal clinics, malaria risk, 
and population density all vary substantially within most 
countries and national aggregates of intervention use 
might mask important targeting of resources to areas 
with a high malaria risk or inequities in intervention 
coverage among marginalised communities in such 
areas. We aimed to analyse subnational intervention 
coverage congruent with modelled malaria risk to better 
understand the targeted coverage of insecticide treated 
nets and intermittent preventive treatment in pregnant 
women who are most likely to beneﬁ t from universal 
coverage of these interventions.
Methods
Data collection and study population
We identiﬁ ed national malaria prevention policies for 
pregnant women and approximate year of policy adoption 
from the World Malaria Report10 and proposals submitted 
to the Global Fund to Fight AIDS, Tuberculosis and 
Malaria.13 We obtained data from national policies and 
contacted national malaria control programmes. We used 
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date of policy adoption to estimate the time between 
adoption of the policy and national coverage survey year 
because there were no reliable data for the actual timing 
of implementation by country. We documented policy 
ambitions and mechanisms of distribution of insecticide-
treated nets within a country, but the available information 
was insuﬃ  cient to allow useful analysis. Because of 
important diﬀ erences in malaria policy, separate malaria 
control governance and malaria risk, we report separate 
data for north Sudan and south Sudan (the semi-
autonomous region) and for Tanzania mainland and the 
islands of Zanzibar.
We obtained data for coverage and use of insecticide-
treated nets, intermittent preventive treatment, and 
antenatal care from national household cluster-sample 
surveys done as part of demographic and health surveys,14 
multiple indicator cluster surveys,15 malaria indicator 
surveys,16 and a survey done by the Food Security and 
Nutrition Analysis Unit (FSNAU) in Somalia.17 The 
multistage sampling design from ﬁ rst-level administration 
(eg, province, state, or region) to national census-deﬁ ned 
enumeration clusters is common to all these surveys, 
and sample sizes are established to provide precision in 
health and population indicators at the ﬁ rst-level 
administrative unit (ADMIN1). For three national surveys 
(Nigeria, Tanzania, and Madagascar), sampling precision 
was increased to provide estimates of intervention 
coverage at second-level administrative units (eg, 
districts) and we have used these sampling units in this 
analysis. For every country, we identiﬁ ed the most recent 
surveys that collected information about use of 
insecticide-treated nets, intermittent preventive 
treatment, and antenatal care from pregnant women. We 
included surveys if they were done during or after 2004. 
No intervention coverage data were available in this 
period for Botswana, Cape Verde, Comoros, Eritrea, 
Gabon, South Africa, and south Sudan. We matched all 
estimates of insecticide-treated nets and intermittent 
preventive treatment coverage to digitised administrative 
boundaries reported by the national surveys with sources 
and methods described previously using ArcGIS 9.1 
(ESRI, NY, USA).18
Study populations for insecticide-treated net use 
included pregnant women, women aged 15–49 years, 
and, for three surveys (Côte d’Ivoire, Malawi, and 
Mozambique), women who had a pregnancy in the 
2 years before the survey.19–21 Sample sizes in pregnant 
women at the ADMIN1 level were frequently small. To 
increase the power of the analysis for coverage, we 
computed the correlation between insecticide-treated 
net use in pregnant women and women aged 15–49 years 
(webappendix pp 1–2). This correlation was strong 
(r²=0·9, p<0·0001) and therefore we used coverage 
among women aged 15–49 years as a proxy for coverage 
among pregnant women. We deﬁ ned coverage from 
survey data as reported use of an insecticide-treated net 
the night before the survey; most surveys deﬁ ned an 
insecticide-treated net as one that was treated in the past 
12 months or a longlasting insecticide-treated net. Three 
surveys (Djibouti, Mauritania, and north Sudan) used 
insecticide treatment in the previous 6 months to deﬁ ne 
insecticide-treated nets.22–24
Study populations for intermittent preventive treatment 
included women aged 15–49 years who gave birth in the 
previous 2 or 5 years for the last birth, pregnant women, 
or women with a birth in the past year. Intermittent 
preventive treatment was deﬁ ned as sulfadoxine–
pyrimethamine provided at predeﬁ ned intervals during 
pregnancy. WHO recommends that all pregnant women 
in stable malaria transmission areas receive at least two 
doses of sulfadoxine–pyrimethamine, at the ﬁ rst and 
second routine antenatal clinic visit after quickening 
(ﬁ rst baby movements felt by the mother), and at least 
1 month apart.3 The survey indicator closest to this 
deﬁ nition was at least two doses of sulfadoxine–
pyrimethamine during an antenatal clinic visit. However, 
only six countries used this deﬁ nition;24–29 13 other 
countries used a broader deﬁ nition of at least two doses 
of sulfadoxine–pyrimethamine, of which at least one was 
from the antenatal clinic. We therefore categorised 
intermittent preventive treatment into four indicators: 
ﬁ rst, at least one dose from any source; second, at least 
one dose from an antenatal clinic; third, two or more 
doses from any source; and fourth, two or more doses, at 
least one of which was received during an antenatal clinic 
visit. The ﬁ rst indicator was the most commonly available 
(39 data sources) and was therefore used to map coverage 
of intermittent preventive treatment. For Niger and north 
Sudan, data were only available for the third indicator so 
these were used as a proxy for the ﬁ rst indicator.
We used published data for the limits and intensity of 
Plasmodium falciparum transmission (webappendix 
pp 3–4)30–33 that deﬁ ned malaria risk in 2007 on the basis 
of a continuous scale of predicted annual mean 
prevalence in children aged 2–10 years (PfPR2–10), and 
categorised ADMIN1 regions as high-intensity trans-
mission (PfPR2–10 ≥40%), medium-intensity transmission 
(PfPR2–10 10–39%), or low-intensity transmission 
(PfPR2–10 <10%; ﬁ gure 1A).
To obtain estimates of the number of births per year, 
we used the national estimates of the annual number of 
livebirths for 2005–10 from the 2008 revision of the 
population database of the UN Population Division,34 and 
added estimates of stillbirths projected for 2007 as 
reported previously.2 To obtain population size by 
ADMIN1 for 2007, we used the population data from the 
Global Rural Urban Mapping Project, providing 
1×1 gridded population counts in ArcView 3.2 (ESRI) as 
described in detail previously.31,35 We distributed the 
estimated total number of pregnancies at risk of malaria 
in proportion to the estimated 2007 population at risk of 
malaria (PfPR2–10 >0) by ADMIN1; we excluded an 
estimated 122 000 pregnancies in eight ADMIN1 regions 
without malaria (Addis Ababa in Ethiopia, Erongo, 
See Online for webappendix
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Figure 1: Malaria risk (A), 
IPTp policy adoption (B), 
ITN coverage in women aged 
15–49 years (C), 
IPTp coverage of at least one 
dose of sulfadoxine–
pyrimethamine from 
any source (D), and ANC 
coverage (E) in countries in 
sub-Saharan Africa
Ethiopia and Burundi have no 
IPTp policy (D), but data were 
collected for sulfadoxine–
pyrimethamine use in 
pregnant women in the 
last-available survey; 
Mauritania, Congo, and the 
Central African Republic had 
no IPTp policy at the time of 
the survey; Chad and Guinea 
adopted IPTp <1 year before 
the survey. ADMIN1=ﬁ rst-level 
administrative unit. 
IPTp=intermittent preventive 
treatment in pregnancy. 
ITN=insecticide-treated net. 
ANC=antenatal clinic.
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Hardap, and Karas in Namibia, Hhohho and Shiselweni 
in Swaziland, and Bulawayo and Harare in Zimbabwe).
Modelling procedures and assumptions
With coverage data obtained from surveys done in 
2004–09, we estimated the absolute number of pregnancies 
that would have been protected or unprotected for malaria 
in a country at the national scale and by malaria-
transmission level for a hypothetical pregnant population 
in 2007 (ﬁ gure 2). Because intermittent preventive 
treatment is provided in the second and third trimester 
only, the number of pregnancies was deﬁ ned as the 
number of livebirths plus stillbirths (ie, induced and 
spontaneous abortions were not taken into account). 
Because demographic data for birth rates were not 
available at all ADMIN1 levels, national statistics were 
applied to each underlying ADMIN1 level. Each ADMIN1 
level was categorised to a single malaria transmission 
intensity category (eg, diﬀ erences in malaria categories 
within an ADMIN1 were not taken into account). Reported 
insecticide-treated net use in the previous night by women 
aged 15–49 years was used as an indicator for insecticide-
treated net use during pregnancy.
Statistical analysis
We calculated the median (IQR) coverage of use 
of insecticide-treated nets, intermittent preventive 
treatment, and antenatal care by ADMIN1 and stratiﬁ ed 
these data by the three categories of malaria transmission 
intensity. We calculated the number of regions with 
coverage of 60% or more of these interventions and 
assessed the association between time of policy adoption 
and high coverage (≥60%).3 We compared proportions 
with the χ² test or the Fisher’s exact test if appropriate 
and p<0·05 was regarded as signiﬁ cant. All data were 
analysed with SAS version 9.2.
Role of the funding source
The sponsor of the study had no role in study design, 
data collection, data analysis, data interpretation, or 
writing of the report. The corresponding author had full 
access to all the data in the study and had ﬁ nal 
responsibility for the decision to submit for publication.
Results
Apart from Cape Verde and South Africa, all countries 
had a policy to promote insecticide-treated nets for 
pregnant women, which had been adopted gradually 
between 1998 and 2007 (table 1). Most of these 
countries had adopted such a policy by 2004. For many 
countries, the dominant mechanisms used to provide 
insecticide-treated nets to pregnant women were 
diﬃ  cult to establish, but all countries stated antenatal 
clinics as part of their distribution system to target 
pregnant women.
Eight countries (Botswana, Burundi, Cape Verde, 
Djibouti, Eritrea, Ethiopia, Swaziland, and South Africa) 
did not have any explicit policies related to the provision 
of intermittent preventive treatment in pregnancy. 
Burundi had a policy for screening and treatment during 
antenatal visits.41 Eritrea, which has both 
Plasmodium vivax and P falciparum transmission, has 
kept the option of intermittent preventive treatment in 
its national policy, but, to our knowledge, this has not 
been implemented and chloroquine prophylaxis is 
used.57 No drug policies speciﬁ c to pregnant women 
were provided in the national guidelines in Djibouti, 
Ethiopia, Swaziland, or South Africa. All eight countries 
have a low or unstable risk of P falciparum transmission.31 
The remaining 39 countries had adopted intermittent 
preventive treatment in pregnancy between 1993 
and 2007, mostly between 2004 and 2005 (ﬁ gure 1B, 
table 1). Most countries adopted two doses of 
sulfadoxine–pyrimethamine, although Ghana and 
Zambia recommended three doses. In 2009, Kenya 
changed from two to three or more doses as part of 
focused antenatal care.112 Rwanda stopped intermittent 
preventive treatment in 2008 because of evidence of 
reductions in malaria transmission.28
We obtained data for intervention coverage from 
48 surveys done between 2004 and 2009 (12 multiple 
Figure 2: Flow diagram for calculation of number of pregnancies protected against malaria by ITNs or IPTp in 
sub-Saharan Africa for a hypothetical pregnant population in 2007
IPTp=intermittent preventive treatment in pregnancy. ITN= insecticide-treated net. ANC=antenatal clinic. 
PfPR2–10=predicted annual mean prevalence of Plasmodium falciparum in children aged 2–10 years. 
ADMIN1=ﬁ rst-level administrative unit.
48 surveys identiﬁed between 2004 and 2009
20 from demographic and health surveys14
12 from multiple indicator cluster surveys15
15 from malaria indicator surveys16
1 from an alternative source17
Mean population-weighted PfPR2–10 in 2007 by ADMIN1. 
Areas were categorised into:
No risk of Plasmodium falciparum malaria (areas 
excluded from calculations)
Low-intensity transmission (<10%)
Medium-intensity transmission (10–39%)
High-intensity transmission (≥40%)
Estimated number of livebirths nationally34
Births were medium variant in 2005–10
Stillbirths for 2007 in areas at risk of P falciparum2 
Population size by ADMIN 1 were provided by the 
Globl Rural Urban Mapping Project for 1×1 gridded 
population counts in ArcView 3·2 projected for 200735
We distributed the sum of national number of live and 
stillbirths by ADMIN 1 proportional to population size
Information about use of IPTp, ITN, and ANCs at 
the national and subnational scale (ADMIN1) in 
sub-Saharan Africa between 2004 and 2009 
Data for P falciparum risk by ADMIN1 for 2007
Number of livebirths and stillbirths (estimated 
number of pregnancies for ITN and IPTp coverage) 
per country and ADMIN1 projected for 2007
Projected for 2007
Number of pregnancies covered by ITN
Coverage among women 15–49 years used as 
proxy
Number of pregnancies in country or ADMIN1 
multiplied by coverage in surveys 2004–09
Stratiﬁcation by malaria category and ADMIN1
Number of pregnancies where IPTp was used
Number of pregnancies in country of ADMIN1 
multiplied by coverage in surveys in 2004–09
Stratiﬁcation by malaria category and ADMIN1
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ANC-Malaria in pregnancy policy ITNs for pregnant women Distribution systems (approximate year adopted) IRS (year 
adopted)
Last survey
Drug (number of 
doses)
Start 
year
Policy ambition Target (year 
adopted)
Policy 
ambition
Angola10,36 IPTp with SP (two) 2005 2011: 80% IPT2 Yes (2000) 2012: 80% FMCN (2005), RFD (ANC 2001), free of charge to 
vulnerable groups (2001), SPPS (2005) 
Yes (2003) MIS 2006–07
Benin37,38 IPTp with SP (two) 2005 2005: 
60% (prevention); 
2010: 80% IPT
Yes (2002) 2005: 60%; 
2010: 80% 
FMCN, RFD (ANC), SPPS, HSrp Yes (2008) DHS 2006
Botswana39 Chloroquine and 
proguanil
Not 
clear
2011: 100% in ANC 
visitors
Yes (2006) 2011: >60% SPPS, RFD (ANC), HSrp Yes (1950s) None available
Burkina Faso10,40 IPTp with SP (two) 2005 2010: 80% IPT2 Yes (2004) 2010: 80% FMCN (2005), RFD (ANC 2005), SPPS (2005), free (2007) No MICS 2006
Burundi41,42 None ·· ·· Yes (2002) 2005: 50%; 
2007: 60%; 
2010: 80%
FMCN, RFD (ANC), free Yes (2008) MICS 2005
Cameroon10,43 IPTp with SP (two) 2004 2006: 60% IPT; 
2007: 75% IPT; 
2014: 80% IPT2
Yes (2003) 2006: 60%; 
2014: 80%
FMCN (2007), RFD (ANC 2003), SPPS (2005), free (2003) No MICS 2006
Cape Verde44 Chloroquine ·· None No None ·· No None available
Central African 
Republic45
IPTp with SP (two) 2007 2005: 60% IPT; 
2011: 80% IPT
Yes (2007) 2005: 60%; 
2012: 80%
FMCN, RFD (ANC), free No MICS 2006
Chad10,46 IPTp with SP (two) 2004 2013: 80% IPT in 
ANC attendees
Yes (2003) 2013: 80% FMCN (2006), RFD (ANC 2003), free (2003) No DHS 2004
Comoros47,48 IPTp with SP (two) 2003 2004: 45% IPT; 
2014: 80% IPT
Yes (2001) 2005: 50%; 
2012: 80%*
FMCN, RFD (ANC 2007), free Yes (2007) None available
Congo49,50† IPTp with SP (two) 2006 Not clear Yes (2004) Not clear FMCN, RFD (ANC), free No DHS 2005
Côte d’Ivoire10,51 IPTp with SP (two) 2005 2011: 80% IPT Yes (2005) 2011: 80% FMCN (2006), RFD (ANC 2006), free (2006) No MICS 2006
Djibouti52,53 None ·· ·· Yes (2000) 2010: 80% FMCN, RFD (ANC), free Yes (1990s) MIS 2008–09
DR Congo10,54 IPTp with SP (two) 2004 2011: 80% IPT Yes (2006) 2011: 80% FMCN (2003), RFD (ANC 2003), free (2006), SPPS (2003) Yes (2008) DHS 2007
Equatorial 
Guinea55,56
IPTp with SP (two) 2005 2010: 80% IPT Yes (2007) 2009: 50%; 
2010: 60%
FMCN, RFD, free Yes (2004) MIS 2009
Eritrea57,58 Chloroquine 2005 2009: 35%‡ Yes (2005) 2007: 80%; 
2009: 90%; 
2014: 90%
Free to residents of areas with malaria, RFD (ANC) Yes (2000) None available
Ethiopia10,59 None ·· ·· Yes (2001) 2010: 100% FMCN (2006), SPPS 2004, RFD (ANC 2006), free (2004) Yes (1997) MIS 2007; DHS 
2005
Gabon60,61 IPTp with SP (two) 2003 2007: 60% IPT; 
2010: 80% IPT
Yes (2003) 2007: 60% RFD (ANC 2005), free, FMCN No None available
Gambia62,63 IPTp with SP (two) 2003 2005: 60% IPT2; 
2007: 70% IPT2; 
2015: 80% IPT2
Yes (2002) 2005: 60%; 
2009: 90%; 
2015: 90%*
RFD (ANC 2002), free Yes (2008) MIS 2008
Ghana10,64,65 IPTp with SP 
(three)
2003 2010: 60% IPT; 
2015: 100% IPT2
Yes (1999) 2010: 60%; 
2015: 85%
FMCN (2000), RFD (ANC 1999), SPPS (1997), free 
(2006)
Yes (2005) DHS 2008
Guinea66,67 IPTp with SP (two) 2005 2006: 80% IPT; 
2010: 80% IPT2
Yes (2002) 2006: 30%; 
2010: 60%
FMCN, RFD (ANC 2008) No DHS 2005
Guinea-Bissau68,69 IPTp with SP (two) 2004 2009: 60% IPT; 
2011: 80% IPT
Yes (2004) 2009: 60%; 
2011: 80%
FMCN, RFD (ANC 2004), free No MICS 2006
Kenya10,70,71 IPTp with SP (two 
or three)
1999; 
2009
2006: 60% IPT2; 
2013: 50% IPT2
Yes (2001) 2006: 60%; 
2013: 80%
FMCN (2006), RFD (ANC 2005), SPPS (2002), free 
(2006)
No DHS 2008
Liberia72 IPTp with SP (two) 2004 2010: 75% IPT; 
2013: 95% IPT
Yes (2004) 2010: 60%; 
2013: 85%
FMCN, RFD (ANC), free No MIS 2008–09
Madagascar10,73 IPTp with SP (two) 2004 2010: 80% IPT2; 
2012: 80% IPT2
Yes (2000) 2010: 65%; 
2012: 80%
FMCN (2007), RFD (ANC 2005), SPPS (2000), free (2004) Yes (1998) DHS 2008–09
Malawi10,74 IPTp with SP (two) 1993 2010: 90% IPT2 Yes (2002) 2010: 80% RFD (ANC 2002), free (2006) No MICS 2006
Mali10,75,76 IPTp with SP (two) 2003 2011: 80% IPT2; 
2014: 90% IPT2
Yes (2006) 2011: 80%; 
2014: 90% 
FMCN (2005), RFD (ANC 2006), SPPS (2005), free (2005) Yes (2008) DHS 2006
Mauritania77,78 IPTp with SP (two) 2006 2006: 70%; 
2010: 80% IPT1
Yes (2002) 2006: 70%; 
2010: 80%
RFD (ANC), FMCN, free No MICS 2006
Mozambique10,79 IPTp with SP (two) 2006 2007: 60% IPT1; 
2010: 80% IPT1
Yes (2003) 2007: 90%; 
2009: 95% 
RFD (ANC 2003), free (2003) Yes (2005) MIS 2007
(Continues on next page)
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indicator cluster surveys, 20 demographic and health 
surveys, 15 malaria indicator surveys, and one survey 
from the FSNAU in Somalia) in 364 ADMIN1 regions 
from 40 countries (table 2). 27 (56%) of 48 surveys were 
done between 2007 and 2009.
No recent data for insecticide-treated net use in women 
aged 15–49 years or pregnant women were available for 
eight countries (Burkina Faso, Burundi, Cameroon, 
Central African Republic, Chad, Guinea Bissau, São 
Tomé and Princípe, and Togo). Data from 32 countries 
for insecticide-treated net use showed that no country 
reached 60% coverage in women aged 15–49 years 
(table 2). The highest coverage for pregnant and non-
pregnant women was reported in Rwanda (45·2% and 
60·3%, respectively), Zanzibar (43·5% and 51·3%), and 
Madagascar (43·3% and 46·2%). Apart from Rwanda, 
none of the countries was close to achievement of its 
stated policy ambition (table 1). At a subnational level, ten 
ADMIN1 regions had insecticide-treated net coverage 
of 60% or more (one region in Ethiopia, seven in 
Madagascar, one in Senegal, and one in Zambia; 
ﬁ gure 1C). Regions with 5 years or more between the 
ANC-Malaria in pregnancy policy ITNs for pregnant women Distribution systems (approximate year adopted) IRS (year 
adopted)
Last survey
Drug (number of 
doses)
Start 
year
Policy ambition Target (year 
adopted)
Policy 
ambition
(Continued from previous page)
Namibia80–83 IPTp with SP 
(two); ﬁ rst and 
second pregnancy
2005 2006: 60% 
prophylaxis
Yes (2002) 2005: 70%; 
2007: 70%; 
2010: 70% 
FMCN, RFD (ANC), free Yes (before 
2000)
DHS 2006–07; 
MIS 2009
Niger10,84 IPTp with SP (two) 2005 2010: 80% IPT1 Yes (1998) 2010: 80% FMCN (2005), RFD (ANC 2004), SPPS (2003), free (2005) No DHS 2006
Nigeria10,85 IPTp with SP (two) 2004 2010: 90% IPT1 Yes (2001) 2010: 80% FMCN (2006), RFD (ANC 2001), SPPS (2004), free (2001) No DHS 2008
Rwanda27,86§ IPTp with SP (two) 2005–
08
2006: 60% IPT Yes (2000) 2006: 60%; 
2010: 80%; 
2012: 85%
FMCN, RFD (ANC), SPPS, free No DHS 2007–08
São Tomé and 
Príncipe87–89
IPTp with SP (two) 2004 2010: 90% IPT 
(G1/G2)
Yes (2004) Not reported; 
2009: 80% of 
population
FMCN, RFD (ANC), free Yes (2003) MICS 2006
Senegal10,90 IPTp with SP (two) 2004 2010: 80% Yes (1998) 2010: 80% FMCN, RFD (ANC 2005), SPPS 2000, free (1998), HSrp Yes (2007) MIS 2008–09
Sierra Leone91 IPTp with SP (two) 2004 2008: 60% IPT; 
2015: 80% IPT2
Yes (2000) 2008: 40%; 
2015: 80%
FMCN (2006), RFD (ANC), free No DHS 2008
Somalia92,93¶ IPTp with SP (two) 2002 2005: 60% IPT2; 
2010: 70% IPT2; 
2015: 80% IPT2
Yes (2002) 2005: 60%; 
2010: 80%; 
2015: 80%
RFD (ANC), free, SPPS, HSrp No FSNAU 
2008–09; 
MICS 2006
South Africa94 No ·· ·· No ·· ·· Yes (2000) None available
Sudan (north)10,95 IPTp with SP (two) 2005 2012: 60% IPT Yes (2001) 2012: 80% FMCN (2008), RFD (ANC 2007), SPPS (2002), free (2001) No MIS 2009
Sudan (south)10,96 IPTp with SP (two) 2005 2011: 60% IPT2 Yes (2004) 2011: 60% FMCN, RFD (ANC) No None available
Swaziland97–99 No|| ·· ·· Yes (2002) 2007: 80% FMCN, RFD (ANC), free Yes (2000) DHS 2006–07
Tanzania10,100,101 IPTp with SP (two) 2001 2007: 60% IPT2; 
2013: 80% IPT2
Yes (2004) 2007: 60%; 
2013: 80%
FMCN (2005), RFD (ANC 2004), SPPS (ANC voucher 
system)
No MIS 2007–08
Togo102,103 IPTp with SP (two) 2003 2006: 70% IPT; 
2010: 80% IPT
Yes (2001) 2006: 65%; 
2010: 90%
FMCN, RFD (ANC), free No MICS 2006
Uganda10,104 IPTp with SP (two) 2000 2005: 60% IPT2; 
2015: 85% IPT2
Yes (2003) 2005: 60%; 
2010: 85%
FMCN (2004), RFD (ANC 2004), SPPS (2004), free 
(2006), CRps
Yes (2006) DHS 2006
Zambia10,105 IPTp with SP 
(three)
2001 2008: 80% IPT3; 
2011: 90% IPT3
Yes (2000) 2008: 80%; 
2011: 80%
FMCN (2003), RFD (ANC 2001), free (2005), SPPS (2001) Yes (2000) MIS 2008
Zanzibar106–108 IPTp with SP (two) 2001 2008: 70% IPT Yes (2004) 2008: 80% RFD (ANC) Yes (2006) MIS 2007–08
Zimbabwe109–111 IPTp with SP (two 
or three)**
2004 2012: 85% IPT2 
(in ANC attendees)
Yes (2001) 2004: 50%; 
2012: 80%*
FMCN, RFD (ANC), free Yes (1949) DHS 2005–06; 
MIS 2008
Approximate year or ambition information can diﬀ er between and within sources. Policy ambition was percentage of coverage aimed at the national scale. IRS in this table is deﬁ ned as the primary means of 
vector control, not when used only for prevention and control of epidemics. ANC=antenatal clinic.  ITN=insecticide-treated net. IRS=indoor residual spraying. IPTp=intermittent preventive treatment in 
pregnancy. IPT=intermittent preventive treatment. IPT1=ﬁ rst dose of IPT. IPT2=second dose of IPT. SP=sulfadoxine–pyrimethamine. FMCN=national free mass campaigns. RFD=routine free distribution through 
public sector. SPPS=subsidised private or public sector. MIS=malaria indicator survey. HSrp=highly subsidised routine distribution through public sector. DHS=demographic and health survey. MICS=multiple 
indicator cluster survey. G1/G2=Women in their ﬁ rst or second pregnancy. CRps=cost recovery through public sector. FSNAU=Food Security and Nutrition Analysis Unit. *Either ITN or IRS protected. †IPTp in 
Congo needs to have been adopted between 2006 and 2009, ITN for pregnant women needs to have been adopted before 2005, but the year could not be veriﬁ ed from sources. A national strategic plan could 
not be obtained. ‡The national malaria control strategy, 2005–10, intended to “provide an opportunity to initiate chemoprophylaxis and IPT for pregnant mothers who live in highly malarious areas only for 
transmission seasons”;57 however, no chemoprevention or IPTp is mentioned in the Global Fund proposal of 2009; no IPTp was implemented. §Rwanda stopped IPTp in 2008, because of the changed situation 
with regards to malaria transmission.28 ¶Of the countries in this table, Somalia is the only country that did not sign the Abuja declaration in 2000. ||DHS 2006–07 reports intermittent preventive treatment with 
chloroquine, but this is not conﬁ rmed from other sources.97 **Whether IPTp with two or three doses is used according to the national malaria policy draft 2008–13 is not clear.109
Table 1: Malaria prevention policies for pregnant women in sub-Saharan African countries
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adoption of the policy and the survey were more likely to 
have coverage of 60% or more than were regions in which 
the policy was adopted less than 5 years ago (10 [6%] of 174 
vs 0 of 119, p=0·007). Eight of these ten ADMIN1 regions 
were in areas with medium-intensity malaria trans-
mission and two were in areas with high-intensity 
malaria transmission.
We selected areas where information was available 
about insecticide-treated net coverage (32 countries and 
293 ADMIN1 regions) and used a 2007 projected 
population surface to represent the mid-point of survey 
data undertaken between 2004 and 2009. In these areas 
with any intensity of malaria risk, we estimated that 
there were 27·7 million pregnancies, of which a total of 
4·7 million pregnant women would have used an 
insecticide-treated net (17%; table 3). Estimated coverage 
was signiﬁ cantly lower in high-intensity transmission 
areas compared with medium-intensity or low-intensity 
transmission areas (p<0·0001; table 3). 5·9 million 
unprotected pregnancies were in Nigeria (21% of 
unprotected population), 2·8 million in Democratic 
Republic of the Congo (10%), 2·1 million in Ethiopia (8%), 
1·3 million in Uganda (5%), and 1·3 million in Tanzania 
(5%). Survey data were not available to provide 
Source Months % of women 
attending ANC 
≥1 visit (sample size)
% of women receiving 
IPTp ≥1 dose of SP 
(sample size)
ITN use ADMIN1 regions*
% pregnant women 
(sample size)
% non-pregnant 
women (sample size)
Number Number in areas 
of high-intensity 
transmission†
Angola‡ MIS 2006–07 Nov–April 79·8% (1422§) 4·7% (1010¶) 22·0% (269) 14·1% (3322) 4 2 
Benin DHS 2006 July–Nov 88·0% (10 521§) 4·9% (6380¶) 19·6% (1962) 18·7% (18 939) 12 10
Burkina Faso‡ MICS 2006 April–June 85·0% (2368¶) 1·8% (2368¶) ·· ·· 13 13
Burundi‡ MICS 2005|| Sept–Dec 92·5% (2986¶) 3·0% (2986¶) ·· ·· 5 0
Cameroon MICS 2006 May–June 73·7% (2834¶) 8·8% (2834¶) ·· ·· 10 7
Central African Republic‡ MICS 2006 Oct–Dec 69·3% (4126¶) 12·0% (4085¶) ·· ·· 16 13
Chad‡ DHS 2004 July–Dec 42·6% (3719§) 0·3% (3719§) ·· ·· 8 0
Congo DHS 2005 July–Nov 88·2% (3568§) 2·0% (3568§) 4·2% (666) 6·1% (7137) 3 3
Côte d’Ivoire‡ MICS 2006 Aug–Oct 91·0% (3587¶) 11·9% (3587¶) No data 6·1% (3587**††) 11 11
Djibouti‡ MIS 2008–09 Dec–Feb 80·6% (2104§) No data 25·2% (163) 13·1% (5829) 6 0
DR Congo‡ DHS 2007 May–Aug 85·3% (5474§) 16·2% (3435¶) 7·1% (1150) 5·3% (10 553) 11 6
Equatorial Guinea‡,‡‡ MIS 2009 Bioko
MIS 2009 mainland
Aug–Sept
May–June
97·3% (339§§) 
99·6% (259§§) 
29·6% (425§§) 
30·0% (320§§) 
40·1% (197)
31·3% (227)
35·3% (3290)
32·4% (2282)
6 4
Ethiopia‡ MIS 2007¶¶
DHS 2005||
Oct–Dec
April–Aug
No data
27·6% (7308§) 
No data
2·1% (4321¶) 
38·7% (568)
1·1% (1181)
37·1% (6657)
1·4% (14 484)
11 0
Gambia‡ MIS 2008||||
MICS 2005–06
Aug
Dec–March
No data
97·8% (3071¶) 
93·7% (979¶) 
54·7% (3070¶) 
45·0% (402)
No data
40·2% (4094)
No data
5 0
Ghana‡ DHS 2008 Sept–Nov 95·4% (2099§) 58·2% (1177¶) 19·9% (353) 17·4% (10 689) 10 8
Guinea DHS 2005 Feb–June 82·1% (4447§) 4·5% (4447§) 0·4% (772) 0·2% (8130) 8 3
Guinea Bissau‡ MICS 2006 May–June 77·9% (2506¶) 10·3% (2506¶) ·· ·· 4 0
Kenya‡ DHS 2008–09 Nov–Feb 91·5% (3973§) 35·5% (2264¶) 49·0% (601) 41·1% (8849) 8 0
Liberia MIS 2008–09 Dec–March 95·3% (2687§) 57·9% (1573¶) 32·9% (471) 29·0% (4769) 6 6
Madagascar‡ DHS 2008–09 Nov–July 86·3% (8662§) 11·8% (4807¶) 46·2% (1425) 43·3% (17 917) 22 3
Malawi‡ MICS 2006 July–Nov 91·9% (10 552¶) 80·7% (10 552¶) No data 25·6% (10 552¶***) 3 0
Mali‡ DHS 2006 April–Sept 70·4% (9087§) 16·1% (5663¶) 28·9% (1896) 27·8% (15 326) 9 5
Mauritania‡ MICS 2007
DHS 2003–04
May–Sept
Aug–Feb
75·4% (3533¶) 
No data
No data
0·5% (2366§) 
No data
No data
No data
2·0% (5211)
5 0
Mozambique‡ MIS 2007 June–July 87·9% (3093§) 31·4% (1099§§) 7·3% (589) 8·7% (1971¶***) 11 3
Namibia MIS 2009†††
DHS 2006–07
April–June
Oct–March
Not used
94·6% (3898§) 
Not used
27·8% (2054¶) 
25·9% (194)
8·8% (541)
24·8% (3282)
6·8% (10 626)
13 0
Niger DHS 2006 Jan–July 46·4% (6301§) 0·3% (6301§) 6·7% (1311) 6·1% (8924) 8 0
Nigeria‡ DHS 2008 June–Oct 57·7% (17 635§) 10·9% (11 027¶) 4·8% (3397) 3·9%  (33 705) 37 37
Rwanda‡ DHS 2007–08 Dec–April 95·8% (3658§) 53·0% (2267¶) 60·3% (673‡‡‡) 45·2% (7370‡‡‡) 5 0
São Tomé and Príncipe‡ MICS 2006 May–June 97·3% (1231¶) 0·0% (1231¶) ·· ·· 2 0
Senegal‡ MIS 2008–09 Dec–Jan 93·9%** (5406¶) 78·1% (5406¶) 28·5% (2949) 25·3% (20 425) 10 0
Sierra Leone‡ DHS 2008 April–June 86·9% (4103§) 19·5% (2478¶) 27·2% (614) 26·5% (7925) 4 3
(Continues on next page)
Articles
198 www.thelancet.com/infection   Vol 11   March 2011
information about insecticide-treated net coverage for 
around 3·2 million pregnancies in 13 countries that had 
a policy for pregnant women (table 2).
For the ﬁ rst deﬁ nition of coverage with intermittent 
preventive treatment (any number of sulfadoxine–
pyrimethamine doses from any source), national data 
were available for 36 (92%) of 39 countries that had 
adopted an intermittent preventive treatment policy; no 
data were available for Comoros, Gabon, and south 
Sudan. Additionally, data were available for two countries 
which had not adopted intermittent preventive treatment 
(Burundi and Ethiopia). Three countries had not yet 
started intermittent preventive treatment at the time of 
the survey (Central African Republic, DR Congo, and 
Mauritania) and two countries had started less than 
1 year before the survey (Chad and Guinea). These ﬁ ve 
countries are shown in ﬁ gure 1D, but are not included in 
the evaluation of intermittent preventive treatment.
With this deﬁ nition of intermittent preventive treatment, 
ﬁ ve countries had reached national coverage of more than 
60%: The Gambia (99%), Malawi (81%), Zambia (80%), 
Senegal (78%), and Zanzibar (78%; table 2). At a 
subnational level, the median coverage of intermittent 
preventive treatment was 17·8% (IQR 5·7–47·9%; 
293 regions) in 31 countries with such a policy in place for 
1 year or more at the time of the survey. 49 ADMIN1 
regions had coverage of 60% or more (ﬁ gure 1D), 
including all regions in The Gambia, Malawi, and 
Zanzibar, six regions in Ghana, three in Liberia, one in 
Mozambique, nine in Senegal, 12 in Tanzania, and eight 
in Zambia. Seven (14%) of 49 ADMIN1 regions with 60% 
or more intermittent preventive treatment coverage were 
in low-intensity transmission areas, 32 (65%) in areas of 
medium-intensity transmission, and ten (20%) in high-
intensity transmission areas. Such regions were more 
likely to be in areas of low-intensity or medium-intensity 
transmission than in areas of high-intensity (39 [24%] 
of 164 vs ten [8%] of 129; χ² test p=0·0005). Regions that 
had 5 years or more between policy adoption and survey 
were more likely to have a coverage of 60% or more 
compared with regions where the policy was adopted 
more recently (25 [48%] of 52 vs 24 [10%] of 241; χ² test 
p<0·0001). For seven countries (Angola, Benin, Burkina 
Faso, Côte d’Ivoire, Namibia, Niger, and Zimbabwe), the 
deﬁ nition of the study population (women who gave birth 
in the previous 2–5 years) included time that occurred 
Source Months % of women 
attending ANC 
≥1 visit (sample size)
% of women receiving 
IPTp ≥1 dose of SP 
(sample size)
ITN use ADMIN1 regions*
% pregnant women 
(sample size)
% non-pregnant 
women (sample size)
Number Number in areas 
of high-intensity 
transmission†
(Continued from previous page)
Somalia‡ FSNAU 2008–09
MICS 2006
Jan–Dec
Aug–Sept
No data
26·1% (2325¶) 
No data
2·2% (2325¶) 
No data
No data
20·9% (10 601)
No data
3 0
Sudan (north)‡ MIS 2009 Oct–Nov 31·3% (1966§§) 2·5% (1966§§) 17·2% (643) 11·6% (7595) 15 0
Swaziland‡ DHS 2006–07 July–Feb 97·1% (2134§) No data§§§ 0·9% (296) 0·3% (5503) 4 0
Tanzania‡ MIS 2007–08 Oct–Feb 97·0% (4995§) 58·4% (2967¶) 26·0% (823) 24·5% (9189) 21 4
Togo‡ MICS 2006 May–June 84·1% (1627¶) 23·2% (1627¶) ·· ·· 5 5
Uganda‡ DHS 2006 May–Oct 93·5% (5035§) 36·6% (3247¶) 10·0% (1019) 10·1% (9026) 9 2
Zambia MIS 2008
DHS 2007
April–May
April–Oct
No data
93·7% (4136§) 
80·0% (2391§) 
86·8% (2631¶) 
43·2% (416)
32·7% (773)
38·9% (4550)
28·2% (7390)
9 0
Zanzibar MIS 2007–08 Oct–Feb 95·7% (131§) 78·4% (77¶) 51·3% (23) 43·5% (313) 2 0
Zimbabwe‡ MIS 2008¶¶¶
DHS 2005–06
No data
Aug–March
No data
94·2% (4099§) 
No data
12·1% (2144¶) 
5·6% (no data)
3·2% (584)
No data
3·0% (8863)
10 0
Botswana, Eritrea, Cape Verde, Comoros, south Sudan, and South Africa were not included because of lack of recent reports (Botswana last report MICS 2000; Comoros MICS 2000; Eritrea DHS 2002, South Africa 
DHS 2003) or lack of a recent report with malaria information (Cape Verde DHS 2005). Eight countries had no recent data for ITN use in women aged 15–49 years or pregnant women. ANC=antenatal clinic. 
IPTp=intermittent preventive treatment in pregnancy. SP=sulfadoxine–pyrimethamine. ITN=insecticide-treated net. ADMIN1=ﬁ rst level administrative region. MIS=malaria indicator survey. DHS=demographic 
and health survey. MICS=multiple indicator cluster survey. ··=not included in questionnaire. FSNAU=Food Security and Nutrition Analysis Unit Somalia (data used from 2008 and 2009). *Second-level 
administrative units used in Nigeria, Madagascar, and Tanzania; areas divided by malaria transmission endemicity in Angola. †Mean Plasmodium falciparum prevalence ≥40% in children aged 2–9 years as 
projected for 2007. ‡MICS4, DHS, or MIS planned in 2009 or 2010. §Aged 15–49 years and gave birth in previous 5 years. ¶Aged 15–49 years and gave birth in previous 2 years. ||Burundi and Ethiopia report SP 
use but is not national policy. **Calculated from dataset. ††Women aged 15–49 years who gave birth in the past 2 years were asked about ITN use during their last pregnancy; this was the only survey that did not 
ask about ITN use during the previous night. ‡‡Two reports were combined, ITN use in women aged ≥15 years was used as proxy for use in women aged 15–49 years; for IPTp, only percentages were available by 
area and, for Bioko, percentages were reported for areas that were smaller than the ADMIN1 region targeted for IPTp, so we combined the percentages with the proportional distribution presented for ANC data 
for these areas. §§Aged 15–49 years with a pregnancy in preceding year or pregnant at the time of the survey for Sudan (north) and Equatorial Guinea. ¶¶Households were included only if at <2500 m altitude. 
||||MIS 2008 was inconsistent about IPTp. Coverage of use of any drugs for prevention of malaria in pregnancy was lower than was that for SP, but no raw data were available to reconcile these diﬀ erences so data 
are presented as in the report. ***Women who gave birth in previous 2 years. †††ANC and IPTp data not used because of small sample sizes (192 in nine regions, only for pregnant women). ITN use only assessed 
in malarious regions of Caprivi, Kavango, Kunene, Ohangwena, Omaheke, Omusati, Oshana, Oshikoto, and Otjozondjupa. ‡‡‡Data only for longlasting ITNs. §§§ IPTp with chloroquine reported. However, 
Swaziland does not have an IPTp policy with SP or chloroquine. ¶¶¶Not Bulawayo or Harare regions; only data for percentage of ITN use in pregnant women by ADMIN1 region were available, so we recalculated 
for women aged 15–49 years with the equation shown in webappendix pp 1–2. IPTp use was not reported.
Table 2: Surveys used and number of women, IPTp coverage, ITN coverage, and ADMIN1 regions in 40 malaria-endemic countries in Africa
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before the adoption of the policy, meaning progress in 
intermittent preventive treatment coverage might have 
been underestimated. Exclusion of these seven countries 
resulted in a median coverage of 23·9% (IQR 9·8–54·2%) 
in the other 227 regions from 24 countries.
When we extrapolated these data for pregnancies in 
areas of any malaria risk in 2007, we estimated that 
there were 25·6 million pregnancies with reported 
information about sulfadoxine–pyrimethamine use 
(table 3), of which 6·4 million (25%) would have been 
protected by at least one dose of this drug. Estimated 
coverage was signiﬁ cantly lower in high-intensity 
transmission areas than it was in areas of medium or 
low intensity (table 3). Among unprotected pregnancies, 
5·4 million (21%) were in Nigeria, 2·4 million (10%) in 
DR Congo, and 1·1 million (4%) in north Sudan. We 
were unable to make any predicted coverage estimates 
for 1·6 million pregnancies occurring in eight countries 
without survey data but with an intermittent preventive 
treatment policy.
For the second deﬁ nition (at least one dose of sulfadoxine–
pyrimethamine from an antenatal clinic), data were 
available for 215 regions in 21 countries. 60% or more 
coverage was reported in 43 ADMIN1 regions in seven 
countries; median coverage was 19·0% (IQR 4·9–50·5%).
For the third deﬁ nition (at least two doses from any 
source), data were available for 257 regions in 28 countries 
with a policy for 1 year or more. Median coverage 
was 12·0% (IQR 5·4–29·1), and 13 regions in ﬁ ve 
countries had a coverage of 60% or more (one each in 
The Gambia, Ghana, and Liberia, three in Senegal, and 
seven in Zambia).
For the fourth deﬁ nition (at least two doses, one from 
an antenatal clinic), data were available for treatment 
coverage for 19 countries and 205 regions; these data are 
stratiﬁ ed by intensity of malaria transmission in ﬁ gure 3 
(the ﬁ rst deﬁ nition is provided for comparison). Only 
Zambia had reached national coverage of 60% or more. 
11 ADMIN1 regions had coverage of 60% or more, ﬁ ve 
regions in Zambia, three in Senegal, and one each in 
Liberia, Ghana, and The Gambia. Two (18%) of these 
11 regions were in high-intensity malaria transmission 
areas, eight (73%) were in medium-intensity transmission 
areas, and one (9%) was in a low-intensity transmission 
Estimated number of 
pregnancies*
Estimated number of 
pregnancies covered (%)†
Estimated number of 
pregnancies not covered (%)
Number of 
ADMIN1 regions
Median coverage 
(IQR)
ITN use (32 countries) 27 674 626 4 702 319 (17·0%) 22 972 307 (83·0%) 293 16·3% (5·6–29·2)
PfPR2–10 <10% 5 926 993 1 672 108 (28·2%) 4 254 885 (71·8%) 59 17·3% (5·6–29·2)
PfPR2–10 10–39% 10 136 161 1 983 298 (19·6%) 8 152 863 (80·4%) 124 22·3% (7·8–39·9)
PfPR2–10 ≥40% 11 611 472 1 046 913 (9·0%) 10 564 559 (91·0%) 110 8·2% (3·3–21·6)
IPTp: any number of sulfadoxine–pyrimethamine doses from any source
All (31 countries) 25 589 128 6 428 875 (25·1%) 19 160 253 (74·9%) 293 17·8% (5·7–47·9)
PfPR2–10 <10% 2 711 228 876 938 (32·3%) 1 834 290 (67·7%) 40 14·6% (3·0–43·7)
PfPR2–10 10–39% 10 112 159 3 420 269 (33·8%) 6 691 890 (66·2%) 124 30·9% (7·6–62·9)
PfPR2–10 ≥40% 12 765 741 2 131 667 (16·7%) 10 634 074 (83·3%) 129 13·8% (5·9–25·0)
IPTp: ≥2 sulfadoxine–pyrimethamine doses (≥1 from an antenatal clinic)
All (19 countries) 20 018 128 2 732 388 (13·6%) 17 285 740 (86·4%) 205 10·2% (3·6–29·2)
PfPR2–10 <10% 2 610 065 472 447 (18·1%) 2 137 618 (81·9%) 38 8·5% (1·3–19·9)
PfPR2–10 10–39% 7 384 418 1 361 741 (18·4%) 6 022 677 (81·6%) 91 15·7% (5·8–41·2)
PfPR2–10 ≥40% 10 023 645 898 199 (9·0%) 9 125 446 (91·0%) 76 6·1% (3·2–20·9)
≥1 antenatal clinic visit
All (40 countries) 30 358 625 21 754 107 (71·7%) 8 604 518 (28·3%) 356 88·4% (68·1–95·2)
PfPR2–10 <10% 5 926 993 2 902 021 (49·0%) 3 024 972 (51·0%) 59 85·5% (30·3–95·1)
PfPR2–10 10–39% 11 273 261 8 999 510 (79·8%) 2 273 751 (20·2%) 149 90·0% (71·4–95·7)
PfPR2–10 ≥40% 13 158 371 9 852 576 (74·9%) 3 305 795 (25·1%) 148 86·2% (70·4–94·0)
≥1 antenatal clinic visit in countries with data for sulfadoxine–pyrimethamine
All (31 countries) 25 589 128 19 784 707 (77·3%) 5 804 421 (22·7%) 293 90·0% (72·6–95·7)
PfPR2–10 <10% 2 711 228 2 026 713 (74·8%) 684 515 (25·2%) 40 92·8% (31·9–95·7)
PfPR2–10 10–39% 10 112 159 8 221 657 (81·3%) 1 890 502 (18·7%) 124 91·7% (79·4–96·5)
PfPR2–10 ≥40% 12 765 741 9 536 337 (74·7%) 3 229 404 (25·3%) 129 88·4% (72·5–95·1)
ANC=antenatal clinic. IPTp=intermittent preventive treatment during pregnancy with sulfadoxine–pyrimethamine. ITN=insecticide-treated net. PfPR2–10=mean prevalence of 
Plasmodium falciparum malaria in children aged 2–10 years (projected for 2007). *Because of an absence of data for number of births by region, we distributed annual 
estimated births per country proportionally to population size by region. †χ² test by malaria transmission level: all comparisons were p<0·0001 apart from ≥1 ANC visits in 
countries with data for sulfadoxine–pyrimethamine, in which there was no signiﬁ cant diﬀ erence between areas of low versus high transmission (p=0·09). 
Table 3: Coverage of prevention for malaria in pregnancy and antenatal clinic use in a hypothetical pregnant population in 2007 in sub-Saharan Africa, 
according to class of Plasmodium falciparum risk by use of survey estimates from 2004–09
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area (χ² test p=0·2). There was a strong correlation 
between intermittent preventive treatment deﬁ ned as 
any number of doses from any source and at least two 
doses of which one from the antenatal clinic (r²=0·9, 
p<0·0001; webappendix pp 1–2).
Antenatal clinics are important distribution points for 
insecticide-treated nets and intermittent preventive 
treatment. Overall, most pregnant women in sub-Saharan 
Africa make at least one antenatal clinic visit (ﬁ gure 1E), 
with a median of 88·4% (IQR 68·1–95·2; 40 countries, 
356 ADMIN1). Six countries had antenatal clinic 
attendance of less than 60% (table 2), which will be a 
major bottleneck to achievement of 60% coverage of inter-
mittent preventive treatment; these countries included 
Chad (42·6%), Ethiopia (27·6%, although there is no 
intermittent preventive treatment policy), Niger (46·4%), 
Nigeria (57·7%), Somalia (26·1%), and north 
Sudan (31·3%). There were substantial inter-regional 
diﬀ erences within Nigeria, with antenatal clinic coverage 
varying from 12·4% in Kebbi State to 97·6% in Anambra 
State.113 All 49 regions with intermittent preven tive 
treatment coverage of 60% or more (≥1 dose, any source) 
were in areas with high antenatal clinic coverage (≥80%), 
whereas 154 of 244 regions (63·1%) with intermittent 
preventive treatment coverage of less than 60% were also 
in areas with high clinic coverage (p<0·0001).
Projected for 2007, 25·6 million pregnancies occurred 
in areas of malaria risk in which data were available for 
antenatal clinic and intermittent preventive treatment 
(one dose from any source) coverage. Of these women, 
19·8 million would have visited an antenatal clinic at 
least once (77·3%). With the assumption that 
6·4 million women received sulfadoxine–
pyrimethamine (≥1 dose) from their visit, 13·4 million 
pregnant women missed an opportunity to receive 
sulfadoxine–pyrimethamine despite making an 
antenatal clinic visit (52% of total; 68% of clinic 
attendees) for the midsurvey period (2004–09), and 
5·8 million (23%) women did not visit an antenatal 
clinic at all. However, this is a conservative estimate, 
because pregnant women might have received the 
drugs from other sources than the antenatal clinic.
Figure 3: Coverage of SP intermittent preventive treatment (A) and estimated number of pregnant women who received at least two doses of SP, one from an ANC, projected for 2007 (B)
SP=sulfadoxine–pyrimethamine. ANC=antenatal clinic. DR Congo=Democratic Republic of the Congo. *Nigeria: 6 150 000 pregnancies per year.
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Discussion 
We ﬁ nd it encouraging that, of 47 sub-Saharan countries 
assessed, 45 had an insecticide-treated net policy and 
39 had an intermittent preventive treatment policy for 
pregnant women. However, from analysis of surveys, it is 
sobering to learn that, projected for 2007, in 32 countries 
with a national policy for an insecticide-treated nets, an 
estimated 23 million pregnancies were unprotected by 
an insecticide-treated net, with no information for 
3·2 million pregnancies in 13 countries. In 31 countries 
with an intermittent preventive treatment policy, 
19 million were unprotected by intermittent preventive 
treatment, and there was no information for 1·6 million 
pregnancies in eight countries with this policy (panel).
In 2000 in Abuja, Nigeria,3 African governments 
pledged to implement measures to ensure that 60% of 
pregnant women in malaria-endemic areas had access 
to eﬀ ective prevention interventions by 2005. By 2006, 
nationally representative coverage data for the core 
indicators for intermittent preventive treatment was 
only available for three countries,11 although insecticide-
treated net coverage was more commonly reported. 
10 years after the Abuja declaration, most malaria-
endemic countries in sub-Saharan Africa have adopted 
intermittent preventive treatment and insecticide-
treated nets as interventions for prevention of malaria 
in pregnancy and the number of countries with 
nationally representative coverage data for either 
intervention has increased to 40 of 47 countries. 
However, very few countries have reached either the 
targets for 2005 set at the Abuja meeting3 in 2000 or 
their own policy ambition, and countries are even 
further away from the more recent Roll Back Malaria 
Initiative targets set for 2010, calling for 80% coverage 
of insecticide-treated nets in all populations and 100% 
coverage of intermittent preventive treatment in 
pregnancy.9 Additionally, coverage was lower in areas 
with high-intensity malaria transmission than it was in 
areas of middle or low intensity, where women are most 
in need and conditions for which most empirical trial 
data support use.
In general, low coverage with intermittent preventive 
treatment and insecticide-treated nets contrasts with 
high antenatal-clinic attendance, with a median of 90% 
by ADMIN1 region for the countries with an intermittent 
preventive treatment policy for a year or more. This 
ﬁ nding suggests that there are missed opportunities 
when women attended clinics but are not given 
intermittent preventive treatment (or insecticide-treated 
nets). Data for frequency of visits or month of start of 
antenatal-clinic visits were only routinely collected and 
reported at the national level in the demographic and 
health survey, so we could not establish the precise 
number of missed opportunities by assessment of 
number of women who visited an antenatal clinic at least 
twice or who started antenatal clinic use before the third 
trimester. So far, several studies have investigated the 
factors aﬀ ecting access and uptake of intermittent 
preventive treatment. Factors identiﬁ ed included unclear 
messages about intermittent preventive treatment in 
pregnancy, especially about timing of the doses, 
sulfadoxine–pyrimethamine stockouts, limited under-
standing of intermittent preventive treatment, late 
enrolment or irregular antenatal clinic visits, and nurse 
underachievement.12,117–120 Intermittent preventive treat-
ment in pregnancy is not as easy to implement as was 
initially expected; experiences with it and insecticide-
treated net implementation have been described in case 
reports and used to develop training materials.12,121,122 
Community-based studies show that, although 
community sensitisation can be used to increase 
antenatal-clinic attendance and intermittent preventive 
treatment uptake,123,124 direct community-based 
Panel: Research in context
Systematic review
We searched PubMed and the Malaria in Pregnancy Library with 
the terms “insecticide treated nets” or “intermittent preventive 
treatment”, and “pregnancy” and “Africa”. We identiﬁ ed three 
studies that reviewed the use of intermittent preventive 
treatment in pregnancy (IPTp) or insecticide-treated nets 
(ITNs) in pregnant women at a national scale: one review 
in 2006 assessing progress of IPTp in ﬁ ve countries with 
nationwide implementation, containing national survey from 
two countries (Malawi demographic and health survey 2000, 
and Kenya demographic and health survey 2003, two or more 
doses of sulfadoxine–pyrimethamine from any source or during 
antenatal clinic visit, 29% and 4%, respectively);11 one study on 
the association between ITN use among pregnant women and 
children, containing data from 15 surveys done in 2003–06 
(the proportion of pregnant women who slept under an ITN 
the previous night ranged from 1·1% to 19·7%);114 and one 
study that reported on equity, and contained data from 
22 countries for use of IPTp (two or more doses) or an 
antimalarial drug during 2006–08 (the range of coverage was 
not presented, but six countries [Zambia, Senegal, Malawi, 
Tanzania, Ghana, and The Gambia] exceeded 20% coverage).115 
Additionally, IPTp and ITN coverage data for pregnant women 
are often presented in progress reports by WHO, the Roll Back 
Malaria Partnership, and United Nations Children’s Fund. For 
example, a UNICEF report116 presented survey data for 2004–08 
for ITN use among pregnant women for 19 countries (coverage 
1–60%), and on IPTp use for 24 countries (indicators used were 
not speciﬁ ed, coverage 0–60%).
Interpretation
We provide a synthesis of national survey data for the 
coverage of malaria prevention in pregnant women in 
sub-Saharan Africa during 2004–09 in the context of the 
status of country policies, including a critical appraisal of the 
survey indicators used. Our study is the ﬁ rst to assess 
coverage of IPTp and ITNs subnationally, stratiﬁ ed by malaria 
endemicity, and to estimate coverage at the population level.
For the Malaria in Pregnancy 
Library see http://www.update-
software.com/Publications/
Malaria/
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distribution of intermittent preventive treatment risks 
diverting women away from antenatal clinics.125 The need 
to change, due to resistance, from sulfadoxine–
pyrimethamine to drug combinations that might need 
more than 1 day for a treatment course will add to the 
complexities and challenges of delivery, access, and 
adherence. Together with the decreasing prevalence of 
malaria in some regions, these events might cause some 
countries to reconsider the relevance of their intermittent 
preventive treatment policy, as occurred in Rwanda. 
Unfortunately there are no guidelines about when the 
risk–beneﬁ t balance no longer favours intermittent 
preventive treatment, and these are urgently required; 
once the system has been stopped, reinstating of 
intermittent preventive treatment with another drug 
might be diﬃ  cult.
The Roll Back Malaria Initiative guidelines126,127 
published in 2004 and revised in 2009 recommend 
“proportion of pregnant women who slept under an 
insecticide-treated net the previous night” as the 
indicator of insecticide-treated net use. Small sample 
sizes lead to low precision estimates, and a wide range 
of possible results. We therefore used the indicator of 
insecticide-treated net use in women of fertile age as a 
proxy for insecticide-treated net use in pregnant women. 
Although not ideal, this approach reduced the frequently 
mentioned disadvantage that women in their early stage 
of pregnancy and adolescents might not declare 
themselves pregnant, leading to a distortion of the 
indicator among pregnant women.127 Conversely, wide-
scale insecticide-treated net delivery and promotion 
eﬀ orts directed at pregnant women might result in 
higher rates of use in pregnant women, such that use of 
this proxy leads to an underestimate of true coverage. 
There was, however, a strong correlation between these 
two indicators (webappendix pp 1–2), which should be 
expected because pregnancy is a comparatively common 
occurrence in women in the fertile age range in sub-
Saharan Africa.
Our deﬁ nition of insecticide-treated net coverage was 
insecticide-treated net use during the previous night as 
reported by women, which has several limitations. 
Reported use might not be actual use, or use can be 
seasonal depending on the perceived nuisance of 
mosquitoes, and thus the time of survey can aﬀ ect the 
rates obtained.128 Generally, information about source or 
the age of the net was not available from these national 
surveys; old nets need to be replaced, nets might have 
been discarded after the survey, and as such surveys can 
overestimate coverage. Conversely, new distribution 
campaigns after the survey could lead to an underestimate 
of use. Attainment and maintenance of high coverage of 
treated nets is challenging because of the complexity of 
logistics, the changing willingness to use nets, and the 
lifespan of the net.129,130 Immunisation campaigns have 
been eﬀ ective at quickly reaching vulnerable 
populations,131 but campaigns alone will not be suﬃ  cient 
to expand and sustain coverage in response to the call for 
universal coverage.9,132,133 Although distribution of 
insecticide-treated nets to pregnant women through 
antenatal clinics is an attractive option, acquisition will 
depend on timing of the ﬁ rst antenatal visit, and might 
leave women unprotected in the susceptible ﬁ rst 
trimester.134
The ﬁ rst Roll Back Malaria Initiative guidelines126 for 
intermittent preventive treatment in vulnerable popula-
tions were vague and recommended the “proportion of 
women who received intermittent preventive treatment 
for malaria during their last pregnancy” in “women who 
delivered a live baby within the last 5 years” as the 
indicator, with no suggestion of number or source of 
doses. The revised Roll Back Malaria Initiative guidelines 
were more speciﬁ c and recommended assessment of 
“two or more doses of a recommended antimalarial drug 
treatment during antenatal clinic visits to prevent malaria 
during their last pregnancy that led to a livebirth within 
the last 2 years”.127 With both these deﬁ nitions, recall bias 
could be an issue. The only guidelines speciﬁ cally 
developed by WHO for key indicators for malaria in 
pregnancy do not list intermittent preventive treatment 
in pregnancy as an indicator to be measured in household 
surveys.135 A uniform approach to measurement of 
progress in coverage of intermittent preventive treatment 
is needed, and although the revised guidelines provide 
greater clarity on what to measure, this is not yet common 
practice. However, correlation between the diﬀ erent 
indicators used in this report was good, and might 
temporarily help countries to make estimations of 
coverage of intermittent preventive treatment 
(webappendix pp 1–2). A larger gap between the two 
indicators can be expected in areas where the antenatal 
clinic is not the main source of sulfadoxine–
pyrimethamine (eg, distribution by shops or health 
workers).
Routine surveys focus on measurement of intervention-
speciﬁ c coverage indicators; there is no recognised or 
recommended combined indicator. The results from 
trials of combined interventions are not uniform, but use 
of both insecticide-treated nets and intermittent 
preventive treatment during pregnancy seems to be of 
beneﬁ t.136–139 Treated nets have the additional beneﬁ t of 
providing protection to the mother before, during, and 
after pregnancy, and potentially to infants.
Because of the time lag between policy adoption and 
implementation (sometimes as long as 4 years), use of 
the implementation year in the timeframe would have 
been preferable to our use of policy-adoption year, but 
these data were hard to ﬁ nd from available sources. 
Although we retrieved many data sources to assess the 
year of policy adoption for treated nets and intermittent 
preventive treatment for pregnant women, dates often 
varied among the sources such that assignment of the 
year of policy adoption was not obvious. Additionally, 
information was sometimes inconsistent dependent on 
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the source. Both factors might have aﬀ ected our analysis. 
A central, publically available database reporting all 
national policies would be beneﬁ cial to future studies. 
We used available national surveys for this study; the 
surveys therefore covered diﬀ erent timeframes, and not 
all these surveys were recent (only nine surveys were 
done in 2009), limiting our results. Typically, surveys 
have a 3–5-year cycle staggered across Africa, although 
malaria indicator surveys are implemented more 
frequently. Coverage might have improved in the time 
between the survey and analysis, and our results might 
underestimate the true situation. If surveys are most 
likely to occur in countries that are active in malaria 
control, we might have assessed the most active countries, 
and therefore we could have overestimated the situation. 
Malaria indicator surveys are not always publicly available, 
and might not have the depth of detail that is needed for 
this type of analysis (eg, surveys were not done at the 
administrative level desired, or the sample sizes for 
pregnant women were too small).
Some countries aim to protect vulnerable populations 
with insecticide-treated nets and indoor residual 
spraying. Spraying can potentially aﬀ ect the coverage of 
insecticide-treated nets; for example, in an area where 
spraying is done, people might be less motivated to use 
treated nets. 24 countries reported the use of spraying 
as a main technique for reduction of the burden of 
malaria. Most countries adopted indoor residual 
spraying recently; and only ﬁ ve countries reported use 
before 2000. Of the surveys we analysed, 13 reported the 
percentage of houses sprayed in the 12 months before 
the survey (>40% in Equatorial Guinea, Mozambique, 
Zambia, and Zanzibar). Apart from Zanzibar, in which 
insecticide-treated net coverage was 44%, these countries 
had insecticide-treated net coverage of less than 40% 
(Pearson’s  for correlation 0·4; p=0·2). Therefore, on 
the basis of a few countries, at the national level there 
does not seem to be an eﬀ ect of indoor residual spraying 
on the use of insecticide-treated nets, though coverage 
for each intervention was generally low. In the future, 
when indoor residual spraying might be increasingly 
used, it will be important that this indicator is 
standardised and documented at national and 
subnational levels, and separately reported for vulnerable 
groups, such as children younger than 5 years or 
pregnant women.19
We have used the malaria transmission map for 
P falciparum to assign malaria endemicity to the 
administrative regions used in the analysis.31 Malaria 
endemicity can change within short distances and the 
use of PfPR2–10 per ADMIN1 might not accurately 
represent these changes. Additionally, changes in PfPR2–10 
will occur because of ongoing malaria control eﬀ orts, 
and these might not be represented in the map; the high 
coverage of Malaria in Pregnancy prevention measured 
in medium-intensity transmission areas might be related 
to a decline in malaria transmission associated with 
improved control eﬀ orts. However, the analysis of 
coverage by malaria transmission strata at the time of the 
surveys is suﬃ  ciently robust to show high-intensity 
transmission areas in which malaria prevention is most 
needed. These maps of malaria risk are often updated 
and reﬁ ned to provide more precise spatial and temporal 
resolutions that will provide a future tracking method to 
examine inequities in intervention coverage by intensity 
of P falciparum transmission.
Thus, most countries in sub-Saharan Africa have 
adopted national policies aimed at reduction and control 
of malaria in pregnancy. The periodicity of routine 
survey data collection means that up-to-date information 
is scarce, but from the surveys included in our analysis, 
with some notable exceptions, we show not enough 
progress has been made towards the new Roll Back 
Malaria Initiative goals or the policy ambitions of each 
country. With only 5 years in which to meet the 
Millennium Development Goals (and speciﬁ cally for 
malaria, goals 4, 5, and 6),140 coverage rates of two key 
interventions are not on course in most countries in 
sub-Saharan Africa to meet targets. The largest 
diﬀ erences in coverage rates could be made in 
DR Congo and Nigeria.
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